North America 6.78% Growth In Intraocular Lens (iols) Market Size and Overview North America 6.

Welcome to another edition of CEDARS/ASPENS Debates. CEDARS/ASPENS is a society of cornea, cataract and refractive surgery specialists, here to discuss some of the latest hot topics in ophthalmology. At the time of cataract surgery, patients with coexisting ocular pathologies or visual disorders often ask what lenses we can offer to have spectacle-free vision. Difficult eyes may not be suited for advanced-technology IOLs (ATIOLs), but with many options now available, we can be more confident that some of these patients can have their wish fulfilled. Deborah G. Ristvedt, DO, and Timothy Page,

Welcome to another edition of CEDARS/ASPENS Debates. CEDARS/ASPENS is a society of cornea, cataract and refractive surgery specialists, here to discuss some of the latest hot topics in ophthalmology. At the time of cataract surgery, patients with coexisting ocular pathologies or visual disorders often ask what lenses we can offer to have spectacle-free vision. Difficult eyes may not be suited for advanced-technology IOLs (ATIOLs), but with many options now available, we can be more confident that some of these patients can have their wish fulfilled. Deborah G. Ristvedt, DO, and Timothy Page,

Welcome to another edition of CEDARS/ASPENS Debates. CEDARS/ASPENS is a society of cornea, cataract and refractive surgery specialists, here to discuss some of the latest hot topics in ophthalmology. At the time of cataract surgery, patients with coexisting ocular pathologies or visual disorders often ask what lenses we can offer to have spectacle-free vision. Difficult eyes may not be suited for advanced-technology IOLs (ATIOLs), but with many options now available, we can be more confident that some of these patients can have their wish fulfilled. Deborah G. Ristvedt, DO, and Timothy Page,

Welcome to another edition of CEDARS/ASPENS Debates. CEDARS/ASPENS is a society of cornea, cataract and refractive surgery specialists, here to discuss some of the latest hot topics in ophthalmology. At the time of cataract surgery, patients with coexisting ocular pathologies or visual disorders often ask what lenses we can offer to have spectacle-free vision. Difficult eyes may not be suited for advanced-technology IOLs (ATIOLs), but with many options now available, we can be more confident that some of these patients can have their wish fulfilled. Deborah G. Ristvedt, DO, and Timothy Page,

FDA data illustrate patients’ experiences with visual and clarity issues with IOLs, according to a retrospective observational analysis published in Journal of Refractive Surgery. Idan Hecht, MD, of the department of ophthalmology at Mayo Clinic, and colleagues explored data from the FDA’s Manufacturer and User Facility Device Experience (MAUDE) database to compare visual symptoms and optical clarity concerns across IOL types. “Although the MAUDE database does not inform on device usage and therefore cannot provide incidence estimates, the reports can help characterize the nature and patterns

FDA data illustrate patients’ experiences with visual and clarity issues with IOLs, according to a retrospective observational analysis published in Journal of Refractive Surgery. Idan Hecht, MD, of the department of ophthalmology at Mayo Clinic, and colleagues explored data from the FDA’s Manufacturer and User Facility Device Experience (MAUDE) database to compare visual symptoms and optical clarity concerns across IOL types. “Although the MAUDE database does not inform on device usage and therefore cannot provide incidence estimates, the reports can help characterize the nature and patterns

The Iols Market was valued at USD 4.2 billion in 2025 and is poised to grow from USD 4.

To evaluate the feasibility of (CS) testing using (IMO vifa) and to describe postoperative CS in eyes implanted with three types of intraocular lenses (IOLs).

NEW ORLEANS — Implanting different IOLs in refractive lens exchange may improve patient satisfaction, according to a speaker at Refractive Surgery Subspecialty Day at the American Academy of Ophthalmology meeting. R. Luke Rebenitsch, MD, said when it comes to refractive lens exchange (RLE), it is nearly impossible to promise spectacle independence; instead, the goal should be to make the patient happy with their vision. “RLE surgery is not cataract surgery,” he said in his presentation. “The expectations are extraordinarily high. You have to customize to visual demands. Everyone’s coming in

A 77-year-old woman had silicone plate intraocular lenses (IOLs) implanted bilaterally in 2003. Asymptomatic IOL discoloration was noted in both eyes on routine examination in 2023. A dramatic scarlet red hue was seen in the outer third of the IOL material, more pronounced in the posterior and peripheral regions than in the anterior. The central silicone matrix remained colorless. The boundary seemed discrete. Brown and green IOL discolorations are presumably degenerative; rose is reportedly secondary to rifabutin use and blue from iatrogenesis.

NEW ORLEANS — The ophthalmic market continues to grow each year, driven primarily by an aging population, according to a presenter at Eyecelerator@AAO. During a market update, Kristen Harmon Ingenito, MBA, discussed the factors that will impact the field of ophthalmology through 2030. An increase in privatization and premiumization, or a push toward premium lens options, could be a boon for the specialty, while economic uncertainty, capacity limitations and reimbursement pressures may have a detrimental impact. Moving to 2030, Ingenito projected that surgical glaucoma will grow 11.6%, IOLs will

NEW ORLEANS — The ophthalmic market continues to grow each year, driven primarily by an aging population, according to a presenter at Eyecelerator@AAO. During a market update, Kristen Harmon Ingenito, MBA, discussed the factors that will impact the field of ophthalmology through 2030. An increase in privatization and premiumization, or a push toward premium lens options, could be a boon for the specialty, while economic uncertainty, capacity limitations and reimbursement pressures may have a detrimental impact. Moving to 2030, Ingenito projected that surgical glaucoma will grow 11.6%, IOLs will

Intraocular (IOL) dislocation after cataract surgery is rare, but longitudinal trends point to a steady rise in surgical interventions for dislocated IOLs, at least in part due to an aging demographic.1 Conveniently for patients, many who perform vitrectomy for a dislocated IOL now also routinely handle the secondary IOL implantation. A decade ago, the surgical approach to the latter largely depended on a surgeon’s particular training and anecdotal experience. Although this topic is still capable of generating some spirited debate, it is increasingly driven by data rather than preference.

SpyGlass Pharma announced the acquisition of Advanced Vision Science in an effort to boost its IOL manufacturing capacity, according to a press release. SpyGlass acquired all outstanding stock of Advanced Vision Science (AVS) for $13 million in cash. AVS was a subsidiary of Santen Pharmaceutical and is the current supplier of IOLs for Spyglass at it develops the bimatoprost drug pad-IOL, or BIM-IOL, system, which is under investigation in two phase 3 trials, according to the release. As part of the deal, AVS will continue to supply Santen with some types of IOLs for commercialization in Japan

SpyGlass Pharma announced the acquisition of Advanced Vision Science in an effort to boost its IOL manufacturing capacity, according to a press release. SpyGlass acquired all outstanding stock of Advanced Vision Science (AVS) for $13 million in cash. AVS was a subsidiary of Santen Pharmaceutical and is the current supplier of IOLs for Spyglass at it develops the bimatoprost drug pad-IOL, or BIM-IOL, system, which is under investigation in two phase 3 trials, according to the release. As part of the deal, AVS will continue to supply Santen with some types of IOLs for commercialization in Japan